OrbiMed Asia Fund Keen To Invest In Australian Biopharma
This article was originally published in PharmAsia News
Executive Summary
There are a growing number of Chinese companies coming to Australia for their Phase I clinical trials, OrbiMed Asia Managing Director Jonathan Wang, said during the AusBiotech Invest conference.